XML 93 R25.htm IDEA: XBRL DOCUMENT
v3.19.2

Incentive and Non-statutory Stock Option Plan | 12 Months Ended
--- | ---
Jun. 30, 2019
Share-based Payment Arrangement [Abstract] |
Incentive and Non-statutory Stock Option Plan | NOTE 18 - INCENTIVE AND NON-STATUTORY STOCK OPTION PLAN The Company maintains several Incentive and Non-Statutory Stock Option Plans (“Plans”) for its employees and consultants. Options granted under these Plans to an employee of the Company become exercisable over a period of no longer than ten (10) years and no less than twenty percent (20%) of the shares are exercisable annually. Options are not exercisable, in whole or in part, prior to one (1) year from the date of grant unless the Board of Directors specifically determines otherwise, as provided. Two types of options may be granted under these Plans: (1) Incentive Stock Options (also known as Qualified Stock Options) which may only be issued to employees of the Company and whereby the exercise price of the option is not less than the fair market value of the common stock on the date it was reserved for issuance under the Plan; and (2) Non-statutory Stock Options which may be issued to either employees or consultants of the Company and whereby the exercise price of the option is less than the fair market value of the common stock on the date it was reserved for issuance under the plan. Grants of options may be made to employees and consultants without regard to any performance measures. All options issued pursuant to the Plan are nontransferable and subject to forfeiture. The Plans provide for the grant of equity-based awards, including options, stock appreciation rights, restricted stock awards or performance share awards or any other right or interest relating to shares or cash, to eligible participants. The Plans contemplate the issuance of common stock upon exercise of options or other awards granted to eligible persons under the Plans. Shares issued under the Plans may be both authorized and unissued shares or previously issued shares acquired by the Company. Upon termination or expiration of an unexercised option, stock appreciation right or other stock-based award under the Plans, in whole or in part, the number of shares of common stock subject to such award again becomes available for grant under the Plans. Any shares of restricted stock forfeited as described below will become available for grant. The maximum number of shares that may be granted to any one participant in any calendar year may not exceed 50,000 shares. All options issued pursuant to the Plan are nontransferable and subject to forfeiture. Options granted under the Plans are not generally transferable and must be exercised within 10 years, subject to earlier termination upon termination of the option holder’s employment, but in no event later than the expiration of the option’s term. The exercise price of each option may not be less than the fair market value of a share of the Company’s common stock on the date of grant (except in connection with the assumption or substitution for another option in a manner qualifying under Section 424(a) of the Internal Revenue Code of 1986, as amended. Incentive stock options granted to any participant who owns 10% or more of the Company’s outstanding common stock (a “Ten Percent Shareholder”) must have an exercise price equal to or exceeding 110% of the fair market value of a share of our common stock on the date of the grant and must not be exercisable for longer than five years. Options become vested and exercisable at such times or upon such events and subject to such terms, conditions, performance criteria or restrictions as specified by the Board of Directors. The maximum term of any option granted under the 2015 Plan is ten years, provided that an incentive stock option granted to a Ten Percent Shareholder must have a term not exceeding five years. Under the Plans, a participant may also be awarded a “performance award,” which means that the participant may receive cash, stock or other awards contingent upon achieving performance goals established by the Board of Directors. The Board of Directors may also make “deferred share” awards, which entitle the participant to receive the Company’s stock in the future for services performed between the date of the award and the date the participant may receive the stock. The vesting of deferred share awards may be based on performance criteria and/or continued service with the Company. A participant who is granted a “stock appreciation right” under the Plan has the right to receive all or a percentage of the fair market value of a share of stock on the date of exercise of the stock appreciation right minus the grant price of the stock appreciation right determined by the Board of Directors (but in no event less than the fair market value of the stock on the date of grant). Finally, the Board of Directors may make “restricted stock” awards under the Plans, which are subject to such terms and conditions as the Board of Directors determines and as are set forth in the award agreement related to the restricted stock. As of June 30, 2019, the remaining shares to be granted are 1,000 under 2003 Plan, 7,723 under the 2011 Plan, 249,746 under the 2013 Plan and 296,503 under the 2015 Plan. Options and Warrants A summary of option and warrant activity for the years ended June 30, 2019 and 2018 is presented below: OPTIONS:
|  | # of shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Aggregated Intrinsic Value |
Outstanding and exercisable, June 30, 2017 |  |  | 475,133 |  |  | $ | 4.20 |  |  |  | 1.05 |  |  | $ | 8,413 |
Granted |  |  | - |  |  | $ | 0.00 |  |  |  |  |  |  |  |  |
Exercised |  |  | (420,671 | ) |  | $ | 3.88 |  |  |  |  |  |  |  |  |
Expired / Cancelled |  |  | (1,000 | ) |  | $ | 16.00 |  |  |  |  |  |  |  |  |
Outstanding and exercisable, June 30, 2018 |  |  | 53,462 |  |  | $ | 6.50 |  |  |  | 0.61 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Exercised |  |  | (13,076 | ) |  | $ | 6.50 |  |  |  |  |  |  |  |  |
Expired / Cancelled |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Outstanding and exercisable, June 30, 2019 |  |  | 40,386 |  |  | $ | 6.50 |  |  |  | 0.61 |  |  | $ | - |
The aggregate intrinsic value at June 30, 2019 represents the difference between the Company’s closing stock price of $5.59 and the exercise price of the options. The aggregate intrinsic value at June 30, 2018 represents the difference between the Company’s closing stock price of $5.55 and the exercise price of the options. The following table summarizes information about stock options outstanding and exercisable at June 30, 2019.
Exercise Price |  | Number Outstanding and Exercisable |  |  | Weighted Average Remaining Contractual Life |  |  | Weighted Average Exercise Price |
OPTIONS: |  |  |  |  |  |  |  |  |  |  |  |
$6.50 |  |  | 40,386 |  |  |  | 0.61 |  |  | $ | 6.50 |
Totals |  |  | 40,386 |  |  |  | 0.61 |  |  | $ | 6.50 |
During the year ended June 30, 2019, the Company extended the life of 40,386 options with an exercise price of $6.50, for a period of one year. The Company recorded $43,612 in compensation expense for the extension of these options in the accompanying consolidated financial statements. The fair market value was calculated using the Black-Scholes option pricing model with the following assumptions:
|  | June 30, 2019 |
Risk-free interest rate |  |  | 2.56% |
Expected life |  |  | 1 year |
Expected volatility |  |  | 45% |
Expected dividend |  |  | 0% |
Stock Grants The following table summarizes stock grants awarded as compensation:
|  | # of shares |  |  | Weighted Average Grant Date Fair Value ($) |
Unvested, June 30, 2017 |  |  | 420,199 |  |  | $ | 6.07 |
Granted |  |  | 47,513 |  |  | $ | 5.00 |
Vested |  |  | (309,564 | ) |  | $ | 6.00 |
Forfeited / Cancelled |  |  | (2,500 | ) |  | $ | 5.55 |
Unvested, June 30, 2018 |  |  | 155,648 |  |  | $ | 6.07 |
Granted |  |  | 122,277 |  |  | $ | 5.71 |
Vested |  |  | (191,450 | ) |  | $ | 5.99 |
Forefieted / Cancelled |  |  | (4,960 | ) |  | $ | 6.05 |
Unvested, June 30, 2019 |  |  | 81,515 |  |  | $ | 5.88 |
For the years ended June 30, 2019 and 2018, the Company recorded compensation expense of $1,131,013 and $1,861,445, respectively. The compensation expense related to the unvested stock grants as of June 30, 2019 was $455,505 which will be recognized during the fiscal years 2020 through 2022.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration